Corporate Profile for Ribozyme Pharmaceuticals Inc., dated Aug. 27, 1999.--(BUSINESS WIRE)-- The following Corporate Profile is available for inclusion in your files. News releases for this client are distributed by Business Wire and also become part of the leading databases and online services, including all of the leading Internet-based services. -0-
Published Date: Aug. 27, 1999
Company Name: Ribozyme Pharmaceuticals Inc.
Address: 2950 Wilderness Place
Boulder, Colo. 80301
Main Telephone
Number: 303/449-6500
Internet Home
Page Address
(URL) www.rpi.com
Chief Executive
Officer: Ralph E. Christoffersen, Ph.D.
Chief Financial
Officer: Lawrence E. Bullock
Investor Relations
Contact: Alene A. Holzman
Business number: 303/546-8111
E-mail address: HolzmanA@rpi.com
Public Relations
Contact: Pat Rarus
Business number: 714/557-3663
E-mail address: prarus@aol.com
Industry: Biotechnology/Pharmaceuticals
Trading Symbol/
Exchange: NASDAQ/RZYM
Market Makers: (if public) Hambrecht & Quist
Company description: Ribozyme Ribozyme A ribonucleic acid (RNA) molecule that, like a protein, can catalyze specific biochemical reactions. Examples include self-splicing rRNA and RNase P, both involved in catalyzing RNA processing reactions (that is, the biochemical reactions that convert Pharmaceuticals Inc. (RPI RPI - Rockwell Protocol Interface ) is developing a new class of drugs based on "ribozymes," a form of ribonucleic acid Ribonucleic acid (RNA) One of the two major classes of nucleic acid, mainly involved in translating into proteins the genetic information that is carried in deoxyribonucleic acid (DNA). which has the ability to inhibit protein production. RPI is collaborating with Chiron Corp. for commercialization of ANGIOZYME, a drug for the treatment of solid-tumor cancers, such as breast, prostate, colon, and rectum rectum: see intestine. rectum End segment of the large intestine (see digestion) in which feces accumulate just prior to discharge. It is 5–6 in. (13–15 cm) long and lined with mucous membrane. . This drug, which recently completed successful human clinical trials for Phase Ia and Ib, has large market potential: Some 750,000 new cancer cases are discovered each year, and some 200,000 persons die each year from these cancers in the U.S. alone. RPI is collaborating with Eli Lilly and Company Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company and one of the world's largest corporations. Eli Lilly's global headquarters is located in Indianapolis, Indiana, in the United States. to commercialize HEPTAZYME, a drug treatment for Hepatitis C Hepatitis C Definition Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild. , the most common blood-borne infection in the U.S., infecting some 50,000 Americans each year. Existing therapiesare ineffective in about 50% of cases and have severe side effects Side effects Effects of a proposed project on other parts of the firm. . In addition, RPI has other drugs in the pipeline,with 84 patents issued and another 100 pending. The company's business strategy includes: -- developing identified product candidates -- identify new product candidates -- partner with others to develop products Recent stock price: $4.75; Market Cap: $550,000 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion